JOSLIN DIABETES CENTER, INC. Patent applications |
Patent application number | Title | Published |
20150250826 | ISOLATION AND CHARACTERIZATION OF MUSCLE REGENERATING CELLS - Cell populations enriched for human myogenic progenitors are obtained by selection on the basis of expression of specific cell surface markers. The muscle progenitor cells are characterized as being CD45−, Mac-1−, GlycophorinA−, CD31− and CD34−, ITGA7hi and CD56 intermediate and methods of use thereof. Methods are provided for the separation and characterization of human myogenic cells, which are precursor cells having the ability to form muscle. The cells are identified and isolated from cells found within the pool of muscle satellite cells, located beneath the basal lamina of mature muscle fibers in the muscle tissue. | 09-10-2015 |
20150204874 | PREDICTING AND TREATING DIABETIC COMPLICATIONS - Compositions and methods for diagnosing, predicting risk of and/or treating diabetic nephropathy (DN). | 07-23-2015 |
20150147292 | NOVEL SURFACE MARKERS FOR ADIPOSE TISSUE - The present invention is based in part on the discovery of brown and white fat cell specific surface markers. It has been found that the small amino acid transporter Slca10/Asc1 is a specific surface marker for white adipocytes and that the ligand-gated ion channel P2X5 and the small amino acid transporter Slc36a2 are specific surface markers for brown adipocytes. Having identified these specific white and brown cell surface markers, the present invention provides compositions and methods suitable for the targeting of any number of agents to a white or brown adipose tissue and the identification and isolation of white or brown adipocytes for any number of uses including therapeutic, screening and diagnostic purposes. | 05-28-2015 |
20150141497 | METHODS FOR MODULATING KALLIKREIN (KLKB1) EXPRESSION - Disclosed herein are methods for decreasing kallikrein and treating, preventing, or ameliorating metabolic conditions in an individual in need thereof. Examples of disease conditions that can be treated, prevented, or ameliorated with the administration of antisense compounds targeted to kallikrein include obesity and diabetes. Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing a metabolic condition. | 05-21-2015 |
20140296325 | METHODS AND COMPOSITIONS FOR INDUCING BROWN ADIPOGENESIS - Methods and compositions for treating obesity and related disorders. The methods include the use of stem cells treated with BMP-2, -4, -5, -6 and/or -7. | 10-02-2014 |
20140194353 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NERVOUS DISORDERS ASSOCIATED WITH DIABETES - Compositions and methods for treating neural dysfunction. A exemplary method comprises administering to a subject having a neuropathy, e.g., a cognitive dysfunction or Alzheimer's, a therapeutically effective amount of an insulin or insulin analog, wherein the insulin or insulin analog crosses the BBB and/or a compound that increases SREBP-2 expression or activity in the CNS of the subject. | 07-10-2014 |
20130197058 | INHIBITING STRIATED MUSCLE ACTIVATOR OF RHO (STARS) TO IMPROVE GLYCEMIC CONTROL - Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of Striated Muscle Activator of Rho Signaling (STARS) activity, and methods of identifying new compounds for use in the described methods of treatment. | 08-01-2013 |
20130023491 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE - In the invention provides for a method of stimulating or increasing β-cell replication or growth, by contacting a β-cell with an inhibitor of adenosine kinase (ADK), an inhibitor of S-Adenosylhomocysteine hydrolase (SAHH) or an activator of AMP activated protein kinase (AMPK). | 01-24-2013 |
20120251457 | METHODS AND COMPOSITIONS FOR MODULATING ADIPOCYTE FUNCTION - Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7. | 10-04-2012 |
20120208750 | USE OF PROTEIN KINASE C DELTA (PKCD) INHIBITORS TO TREAT DIABETES, OBESITY, AND HEPATIC STEATOSIS - Described are methods of improving insulin sensitivity, and treating fatty liver disease (including non-alcoholic steatohepatitis (NASH)), by administering specific inhibitors of PKC delta. | 08-16-2012 |
20120141436 | COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY - Compositions and methods for providing an enriched population of mature, glucose-responsive insulin secreting cells, and for modulating insulin expression, activity and secretion in a subject. | 06-07-2012 |
20120135927 | BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF INSULIN RESISTANCE - The present disclosure relates to compositions and methods for treating insulin resistance and/or obesity in a cell and/or a subject. | 05-31-2012 |
20120028895 | Inhibiting Serum Response Factor (SRF) to Improve Glycemic Control - Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment. | 02-02-2012 |
20110281758 | METHODS OF DIAGNOSING AND PREDICTING RENAL DISEASE - This disclosure relates to methods of diagnosing and predicting renal disease, using one, two, or more biomarkers, including sTNFR1, sTNFR2, sFAS, TNF, and IL-6. | 11-17-2011 |
20110165144 | METHODS FOR TREATING RHEUMATOID ARTHRITIS - Provided are methods of treating rheumatoid arthritis by inhibiting Neuromedin U signalling. | 07-07-2011 |
20110117049 | Methods and Compositions for Modulating Adipocyte Function - Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7. | 05-19-2011 |
20110104133 | METHODS AND COMPOSITIONS FOR INDUCING BROWN ADIPOGENESIS - Methods and compositions for treating obesity and related disorders. The methods include the use of Sca-1+ progenitor cells treated with BMP-2, -4, -5, -6, and/or -7. | 05-05-2011 |
20110091587 | PHASE II DETOXIFICATION AND ANTIOXIDANT ACTIVITY - Provided are methods and compositions that enhance Nrf2 (SKN-1) activation of phase II detoxification or antioxidant enzyme transcription, comprising plant extracts (e.g., willow extracts) or active fractions thereof, as well as methods for identifying additional compounds that increase the Nrf2-regulation of those enzymes. | 04-21-2011 |
20110044939 | REGULATORY T CELLS IN ADIPOSE TISSUE - Methods of preventing, delaying, or reducing the development or severity of obesity-associated disorders, including administering Fat-specific regulatory T cells, or administering factors secreted by said T cells. | 02-24-2011 |
20110021468 | TREATMENT OF CARDIOVASCULAR DISEASE WITH SALICYLATES - This invention relates to methods for the treatment of atherosclerotic cardiovascular disease using a non-acetylated forms of salicylate, e.g., salsalate and/or trilisate. | 01-27-2011 |
20100166669 | METHODS OF IMAGING INFLAMMATION IN PANCREATIC ISLETS - Described are non-invasive methods for imaging pancreatic inflammation in living mammals using Magnetic Nanoparticle Probes (MNPs). | 07-01-2010 |
20100160412 | METHODS OF MODULATING METABOLIC MEMORY - Described are methods of identifying modulators of metabolic memory, for the treatment of microvascular complications of diabetes, as well as methods of use thereof. Also described are methods of treating microvascular complications of diabetes by decreasing expression and/or activity of SHP-1. | 06-24-2010 |
20100150885 | METHODS AND COMPOSITIONS FOR INDUCING BROWN ADIPOGENESIS - Methods and compositions for treating obesity and related disorders. The methods include the use of stem cells treated with BMP-2, -4, -5, -6 and/or -7. | 06-17-2010 |
20100135995 | METHODS OF MODULATING ANGIOGENESIS - The present inventors discovered that PKCε is necessary for VEGF signaling through PI3K/Akt-dependent pathways and is involved in MAPK-dependent pathways, thus regulating eNOS activity and DNA synthesis, respectively. Thus differential manipulation of PKCε activity can be used to modify VEGF effects in conditions in which modulation of angiogenesis is desirable (e.g., for treatment of diabetic proliferative retinopathy or to enhance angiogenesis for treatment of peripheral and myocardial ischemia). | 06-03-2010 |
20100010074 | Inhibiting Serum Response Factor (SRF) to Improve Glycemic Control - Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment. | 01-14-2010 |
20090298796 | REDUCING RISK OF TYPE 2 DIABETES (T2D) - This invention relates to methods for reducing chronic subacute inflammatory states associated with obesity and improve glycemia, thereby preventing or delaying the development of type 2 diabetes (T2D) in obese subjects, or subjects with the metabolic syndrome, using non-acetylated forms of salicylate, e.g., salsalate or trilisate. | 12-03-2009 |
20090220973 | OBESITY AND BODY FAT DISTRIBUTION - Described are methods for predicting and diagnosing genetically-based obesity and body fat distribution, and for identifying compounds for the treatment and prevention of obesity. | 09-03-2009 |
20090220954 | METHODS OF DIAGNOSING CARDIOVASCULAR DISEASE - Methods are disclosed for diagnosing increased risk of cardiovascular disease in a subject. | 09-03-2009 |
20090220453 | ENHANCING STEM CELL MOBILIZATION - This invention relates to methods and compositions for enhancing hematopoietic stem cell mobilization by inhibiting early growth response-1 (egr1) activity. | 09-03-2009 |
20090142308 | Methods for treating autoimmune disease by inducing autoantigen-specific regulatory CD4+ T cells - Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual β-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention. | 06-04-2009 |
20080311083 | Methods of Modulating Beta Cell Function - Methods of modulating pancreatic function by modulating MCH signaling in a β cell. | 12-18-2008 |